Detail akcie TuHURA Bio Rg online

Business Summary: TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, TuHURA Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $2.2M to $23.3M. Higher net loss reflects Research and Development increase from $215K to $11.7M (expense), General and administration - gross increase from $1.9M to $7.6M (expense), Stock-based Compensation in R&D increase from $37K to $2.8M (expense).